1T-LSD

1T-LSD (N1-(thiophene-2-carbonyl)-lysergic acid diethylamide) is an acylated derivative of lysergic acid diethylamide (LSD), which has been sold as a designer drug. It was first identified in Japan in 2023 on blotter paper misrepresented as containing 1D-LSD, but which on analysis was determined to contain 1T-LSD instead.[1]

1T-LSD
Clinical data
Routes of
administration		By mouth, under the tongue
Legal status
Legal status
  • UK: In general Uncontrolled
Identifiers
  • (6aR,9R)-N,N-diethyl-7-methyl-4-(thiophen-2-yl)methanoyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
Chemical and physical data
FormulaC25H27N3O2S
Molar mass433.57 g·mol−1
3D model (JSmol)
  • O=C(n1cc2C[C@@H]3C(=C[C@H](CN3C)C(=O)N(CC)CC)c3cccc1c32)c1cccs1

See also

References
  1. Okada Y, Ueno K, Nishiwaki N, Nishimura T, Segawa H, Yamamuro T, et al. (July 2023). "Identification of 1-(thiophene-2-carbonyl)-LSD from blotter paper falsely labeled "1D-LSD"". Forensic Toxicology. doi:10.1007/s11419-023-00668-8. PMID 37421500. S2CID 259374662.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.